The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.

Autor: Souza VC; Oncologia D' Or Salvador, Salvador, Brazil. Electronic address: vcscarrera@gmail.com., Monteiro FSM; Hospital Universitário de Brasília (UNB), Brasília, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Maluf FC; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Werutsky G; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Fabrício VC; Janssen Latin America, Buenos Aires, Argentina., Gidekel R; Janssen Latin America, Buenos Aires, Argentina., Gandur-Quiroga MN; Instituto de Oncologia Ángel H. Roffo, Buenos Aires, Argentina., Freitas MRP; Centro de Pesquisas Oncológicas (CEPON), Florianópolis, Brazil., Luz M; 5Hospital Erasto Gaertner, Curitiba, Brazil., Campos-Gomez S; Centro Oncológico Estatal ISSEMYM, Toluca de Lerdo, Mexico., Junior JAR; A.C. Camargo, São Paulo, Brazil., Bastos DA; Hospital Sírio-Libanês, São Paulo, Brazil., Sade JP; Instituto Alexander Fleming, Buenos Aires, Argentina., da Trindade KM; IEP Oncocentro, Fortaleza, Brazil., Mota ACA; Clínica AMO - Assistência Multidisciplinar em Oncologia, Salvador, Brazil., Fernandes RC; Santa Casa de São Paulo, São Paulo, Brazil., Ruíz AOB; Clínicas Médicas Especializadas NUCARE, Ciudad de Guatemala, Guatemala., Pereira E Silva BD; Hospital São Rafael, São Paulo, Brazil., de Oliveira FNG; CLION, Salvador, Brazil., Cutuli HJ; Asociacion de Beneficencia Hospital Sirio-Libanes, Buenos Aires, Argentina., Nogueira L; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil., Aceituno LFG; Clinica Oncologica, Ciudad de Guatemala, Guatemala., Fernandez M; COIR - Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina., Inman E; ONCOR, Saltillo Coahuila, Mexico., Caitano M; Centro de Oncologia do Paraná, Curitiba, Brazil., Herchenhorn D; Oncologia D'OR/Instituto D'OR de Ensino e Pesquisa, Rio De Janeiro, Brazil., Ardila-Salcedo J; Janssen Latin America, Bogota, Colombia., Pacheco P; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., de Jesus RG; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Gössling G; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Soares A; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Centro Paulista de Oncologia (CPO) - Grupo Oncoclinicas, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil., Fay AP; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Centro de Pesquisa em Oncologia (CPO) - Hospital São Lucas da PUCRS, Porto Alegre, Brazil.
Jazyk: angličtina
Zdroj: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Oct; Vol. 22 (5), pp. 102174. Date of Electronic Publication: 2024 Jul 25.
DOI: 10.1016/j.clgc.2024.102174
Abstrakt: Introduction: Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in a Latin American population remains unknown. This study aimed to explore the prevalence of FGFR mutations and/or fusions in patients with mUC in Latin America (LATAM) and its association with clinicopathological characteristics, Bellmunt's prognostic model, and survival outcomes.
Patients and Methods: A multicenter retrospective cohort study from 2016 to 2019 of patients with mUC from several LACOG LATAM institutions. FGFR alterations were analyzed by real-time PCR and/or next-generation sequencing in tumor samples and clinicopathologic characteristics and survival outcomes data were collected. The prevalence of FGFR, patient characteristics, and treatment in real-world settings were summarized. Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate the associations of FGFR mutation and/or fusion status with median overall survival (mOS), median time to treatment failure (mTTF), and clinicopathological characteristics.
Results: In total, 222 patients were screened. Of these, 196 patients were considered eligible and were included in the analysis. FGFR mutations and/or fusions were found in 35 (17.9%) patients. There was no statistical difference in mOS and mTTF in FGFR-altered and non-altered patients (13.1 vs. 16.8 months, P = .20 and 3.9 vs. 4.1 months, P = .96, respectively). Bellmunt's prognostic model correctly predicted overall survival (P = .049).
Conclusions: This is the largest study evaluating the prevalence of FGFR alterations in patients with mUC in the LATAM population. FGFR alterations in mUC were found in 17.9% of the patients, and the presence of this biomarker was not associated with OS. We validated Bellmunt's prognostic model in this cohort.
Competing Interests: Disclosure Dr. Gustavo Werutsky reports personal fees from AstraZeneca, Bayer, Beigene, Daiichi Sankyo, Genentech/Roche, GSK, Lilly, MSD, Novartis, Pfizer, Sanofi, and Seattle Genetics outside the submitted work. All remaining authors have declared no conflicts of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: